All In Biotech

Drug Trial Radar · NCT03343704

This Study Looks at the Effects of Idarucizumab in Patients Who Take Dabigatran and Need Emergency Surgery or Are Bleeding

A Phase III, Case Series Clinical Study of the Reversal of the Anticoagulant Effects of Dabigatran by Intravenous Administration of Idarucizumab (BI 655075) in Patients Treated With Dabigatran Etexilate Who Have Uncontrolled Bleeding or Require Emergency Surgery or Procedures.

Last checked: Nov 20, 2026Latest source record: Feb 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

19

Actual

Start

Mar 26, 2018

Primary completion

Jul 2, 2020

Study completion Jul 2, 2020

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Nov 17, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective is to demonstrate reversal of the anticoagulant effect of dabigatran in patients treated with dabigatran etexilate who have uncontrolled or life-threatening bleeding requiring urgent intervention, and in patients treated with dabigatran etexilate who require emergency surgery or other invasive procedure. The secondary objectives are to assess the reduction or cessation of bleeding, evaluate the clinical outcomes, safety and the pharmacokinetics of dabigatran in the presence of idarucizumab.

Conditions

  • Hemorrhage

Interventions

  • IdarucizumabDrug

    Intravenous

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Reversal of Anticoagulant Effect of Dabigatran Based on Central Laboratory Determination of Ecarin Clotting TimeTime frame: From the end of first infusion up to 4 hours after the completion of the second infusion on Day 1 of the treatment period.
  2. Maximum Reversal of Anticoagulant Effect of Dabigatran Based on Central Laboratory Determination of Diluted Thrombin TimeTime frame: From the end of first infusion up to 4 hours after the completion of the second infusion on Day 1 of the treatment period.

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing AnZhen Hospital

    Beijing, China

  • Peking University First Hospital

    Beijing, China

  • Cardiovascular Institute and Fu Wai Hospital

    Beijing, China

  • First Affiliated Hospital of Dalian Medical University

    Dalian, China

  • Guangdong Provincial People's Hospital

    Guangzhou, China

  • Sun yet-sen Memorial Hospital, Sun yet-sen Univesity

    Guangzhou, China

  • 2nd Affiliated Hosp Zhejiang University College of Medical

    Hangzhou, China

  • Zhejiang Province People's Hospital

    Hangzhou, China

  • The Second Affiliated Hospital to Nanchang University

    Nanchang, China

  • Jiangsu Province Hospital

    Nanjing, Jiangsu Province, China

  • Shanghai First People's Hospital

    Shanghai, China

  • The First Affiliated Hospital of Xinjiang Medical University

    Ürümqi, China

  • The First Affiliated Hospital of Wenzhou Med College

    Wenzhou, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.